-
Something wrong with this record ?
Detection of minimal residual disease in lung cancer
J. Chudacek, T. Bohanes, J. Klein, A. Benedikova, J. Srovnal, M. Szkorupa, P. Skalicky, J. Skarda, M. Hajduch, C. Neoral
Language English Country Czech Republic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
NT14406
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
- MeSH
- ErbB Receptors genetics MeSH
- Phosphoproteins genetics MeSH
- Glycoproteins genetics MeSH
- Keratin-19 genetics MeSH
- Humans MeSH
- RNA, Messenger blood MeSH
- Biomarkers, Tumor blood MeSH
- Neoplastic Cells, Circulating * MeSH
- Lung Neoplasms blood diagnosis surgery MeSH
- Carcinoma, Non-Small-Cell Lung blood diagnosis surgery MeSH
- Proto-Oncogene Proteins c-met genetics MeSH
- Neoplasm, Residual MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
BACKGROUND: Even after successful radical treatment of lung cancer, patients in stages I and II of the TNM system very frequently suffer recurrence, which end lethally. Detection of subclinical residual disease after surgery is thus one of the most important emerging diagnostic methods. Minimal residual disease (MRD) is defined as the presence of isolated tumor cells or circulating cells in a patient after curative primary tumor removal and at the same time, no clinical signs of cancer. Conventional methods cannot detect minimal residual disease and hence there is a need for detection using new molecular biological methods. METHODS: We searched the PubMed database for original and review articles on minimal residual disease in lung cancer. Search words were "lung cancer", "minimal residual disease" and "detection of minimal residual disease". The publications we found were compared with the results of our own studies on the detection of minimal residual disease in lung cancer and the personal experiences are described. Examination of blood samples from 98 healthy volunteers and bone marrow from 12 patients with non inflammatory and non tumour illness, were used to determine cut-off values for specific markers in the compartments. Subsequently, expression of selected markers in tumor tissue was analysed in a pilot sample of 50 patients with lung cancer and the presence of MRD was measured as expression of values of the tested markers correlated with clinico-pathological characteristics. CONCLUSIONS: Recent studies on other malignancies apart from lung cancer have shown the importance of MRD detection in the determination of disease progression and prognosis. The methods of MRD diagnostics are based on detection of specific tumor markers. Of these, the most specific for lung cancer, appears to be the LunX protein. The best method for determining MRD is probably RT-PCR. Further studies should expand knowledge in this area: to refine understanding of the importance of tumor markers for prognosis, as well as to confirm the significance of these findings in clinical practice.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15033235
- 003
- CZ-PrNML
- 005
- 20191022090841.0
- 007
- ta
- 008
- 151016s2014 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2013.019 $2 doi
- 035 __
- $a (PubMed)23558472
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Chudáček, Josef $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0228773
- 245 10
- $a Detection of minimal residual disease in lung cancer / $c J. Chudacek, T. Bohanes, J. Klein, A. Benedikova, J. Srovnal, M. Szkorupa, P. Skalicky, J. Skarda, M. Hajduch, C. Neoral
- 520 9_
- $a BACKGROUND: Even after successful radical treatment of lung cancer, patients in stages I and II of the TNM system very frequently suffer recurrence, which end lethally. Detection of subclinical residual disease after surgery is thus one of the most important emerging diagnostic methods. Minimal residual disease (MRD) is defined as the presence of isolated tumor cells or circulating cells in a patient after curative primary tumor removal and at the same time, no clinical signs of cancer. Conventional methods cannot detect minimal residual disease and hence there is a need for detection using new molecular biological methods. METHODS: We searched the PubMed database for original and review articles on minimal residual disease in lung cancer. Search words were "lung cancer", "minimal residual disease" and "detection of minimal residual disease". The publications we found were compared with the results of our own studies on the detection of minimal residual disease in lung cancer and the personal experiences are described. Examination of blood samples from 98 healthy volunteers and bone marrow from 12 patients with non inflammatory and non tumour illness, were used to determine cut-off values for specific markers in the compartments. Subsequently, expression of selected markers in tumor tissue was analysed in a pilot sample of 50 patients with lung cancer and the presence of MRD was measured as expression of values of the tested markers correlated with clinico-pathological characteristics. CONCLUSIONS: Recent studies on other malignancies apart from lung cancer have shown the importance of MRD detection in the determination of disease progression and prognosis. The methods of MRD diagnostics are based on detection of specific tumor markers. Of these, the most specific for lung cancer, appears to be the LunX protein. The best method for determining MRD is probably RT-PCR. Further studies should expand knowledge in this area: to refine understanding of the importance of tumor markers for prognosis, as well as to confirm the significance of these findings in clinical practice.
- 650 _2
- $a nemalobuněčný karcinom plic $x krev $x diagnóza $x chirurgie $7 D002289
- 650 _2
- $a glykoproteiny $x genetika $7 D006023
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a keratin-19 $x genetika $7 D053539
- 650 _2
- $a nádory plic $x krev $x diagnóza $x chirurgie $7 D008175
- 650 _2
- $a reziduální nádor $7 D018365
- 650 12
- $a nádorové cirkulující buňky $7 D009360
- 650 _2
- $a fosfoproteiny $x genetika $7 D010750
- 650 _2
- $a protoonkogenní proteiny c-met $x genetika $7 D019859
- 650 _2
- $a messenger RNA $x krev $7 D012333
- 650 _2
- $a erbB receptory $x genetika $7 D066246
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bohanes, Tomáš $7 xx0033707 $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Klein, Jiří, $d 1963- $7 xx0047429 $u Department of Surgery, The District Hospital of Tomas Bata, Zlin
- 700 1_
- $a Benedíková, Andrea $7 xx0169440 $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
- 700 1_
- $a Srovnal, Josef $7 xx0091239 $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
- 700 1_
- $a Szkorupa, Marek $7 xx0145985 $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
- 700 1_
- $a Skalický, Pavel $7 xx0102179 $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Škarda, Jozef $7 xx0098446 $u Institute of Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
- 700 1_
- $a Hajdúch, Marián $7 xx0050218 $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
- 700 1_
- $a Neoral, Čestmír, $d 1952- $7 xx0000421 $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 158, č. 2 (2014), s. 189-193
- 856 41
- $u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20151016 $b ABA008
- 991 __
- $a 20191022091315 $b ABA008
- 999 __
- $a ok $b bmc $g 1095633 $s 916366
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 158 $c 2 $d 189-193 $e 20130402 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- GRA __
- $a NT14406 $p MZ0
- LZP __
- $b NLK118 $a Pubmed-20151016